Skip to search formSkip to main contentSkip to account menu

Rimiducid

Known as: 2-Piperidinecarboxylic acid, 1-(1-Oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-Ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) Ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))- 
A lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903 homodimerizes an analogue of human protein FKBP12 (Fv… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

AP 1903 reagent

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL)
2019
2019
Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation.
283 Background: PSCA, a cell surface protein, is upregulated in many solid tumors and correlates with disease stage. BPX601 is an… 
Highly Cited
2018
Highly Cited
2018
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
2018
2018
Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders
2018
2018
Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)
Background Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) constitutes a curative treatment for children with… 
2018
2018
Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established treatment for children with Acute… 
2018
2018
Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion
Introduction: BPX-501 is an allogeneic product consisting of T cells modified to express the inducible caspase-9 (iC9) safety… 
2017
2017
Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer
This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting… 
2015
2015
Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells
Introduction: Adoptive transfer of T cells, genetically engineered to express chimeric antigen receptors (CARs) containing… 
2015
2015
Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma
Introduction: Use of T cells engineered to express antigen-specific T cell receptors (TCRs) has shown promise as a cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)